NCT06568172 2026-03-19
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Ohio State University Comprehensive Cancer Center
OncoResponse, Inc.
Oncovir, Inc.